DE602005022756D1 - Topische nepafenac-formulierungen - Google Patents

Topische nepafenac-formulierungen

Info

Publication number
DE602005022756D1
DE602005022756D1 DE602005022756T DE602005022756T DE602005022756D1 DE 602005022756 D1 DE602005022756 D1 DE 602005022756D1 DE 602005022756 T DE602005022756 T DE 602005022756T DE 602005022756 T DE602005022756 T DE 602005022756T DE 602005022756 D1 DE602005022756 D1 DE 602005022756D1
Authority
DE
Germany
Prior art keywords
nepafenac formulations
topical
topical nepafenac
formulations
nepafenac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005022756T
Other languages
English (en)
Inventor
Warren Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35848959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005022756(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of DE602005022756D1 publication Critical patent/DE602005022756D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602005022756T 2004-12-02 2005-12-02 Topische nepafenac-formulierungen Active DE602005022756D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63256204P 2004-12-02 2004-12-02
PCT/US2005/043545 WO2006060618A2 (en) 2004-12-02 2005-12-02 Topical nepafenac formulations

Publications (1)

Publication Number Publication Date
DE602005022756D1 true DE602005022756D1 (de) 2010-09-16

Family

ID=35848959

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022756T Active DE602005022756D1 (de) 2004-12-02 2005-12-02 Topische nepafenac-formulierungen

Country Status (24)

Country Link
US (3) US7834059B2 (de)
EP (1) EP1819362B1 (de)
JP (2) JP4968844B2 (de)
KR (1) KR101289661B1 (de)
CN (1) CN101068573A (de)
AR (1) AR052252A1 (de)
AT (1) ATE476200T1 (de)
AU (1) AU2005311738B2 (de)
BR (1) BRPI0518904B1 (de)
CA (1) CA2586807C (de)
CY (1) CY1110780T1 (de)
DE (1) DE602005022756D1 (de)
DK (1) DK1819362T3 (de)
ES (1) ES2348249T3 (de)
HK (1) HK1104225A1 (de)
MX (1) MX2007006558A (de)
PL (1) PL1819362T3 (de)
PT (1) PT1819362E (de)
RU (1) RU2007124638A (de)
SI (1) SI1819362T1 (de)
TW (1) TWI358290B (de)
UY (1) UY29238A1 (de)
WO (1) WO2006060618A2 (de)
ZA (1) ZA200704763B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
ATE412402T1 (de) * 2005-05-10 2008-11-15 Alcon Inc Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen
CN101175475B (zh) * 2005-05-10 2010-04-14 爱尔康公司 包含活性成分、泊洛沙姆或美洛沙泊表面活性剂和二醇的混悬制剂、其用于生产治疗眼科病症的药物的用途
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20080057022A1 (en) * 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
CA2687717A1 (en) * 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
TWI531362B (zh) * 2008-07-21 2016-05-01 艾爾康股份有限公司 具有治療劑遞送能力之眼科裝置
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
WO2010101971A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US8921337B2 (en) 2009-12-03 2014-12-30 Alcon Research, Ltd. Carboxyvinyl polymer-containing nanoparticle suspensions
US9544143B2 (en) 2010-03-03 2017-01-10 Duo Security, Inc. System and method of notifying mobile devices to complete transactions
US9532222B2 (en) 2010-03-03 2016-12-27 Duo Security, Inc. System and method of notifying mobile devices to complete transactions after additional agent verification
US9467463B2 (en) 2011-09-02 2016-10-11 Duo Security, Inc. System and method for assessing vulnerability of a mobile device
RU2014129268A (ru) * 2011-12-16 2016-02-10 Аллерган, Инк. Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
EP3013790A1 (de) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Verfahren zur herstellung von nepafenac
CN104490861A (zh) * 2014-11-21 2015-04-08 三明欣茂药业有限公司 一种缓释型奈帕芬胺眼用制剂
ES2966595T3 (es) 2015-01-26 2024-04-23 Bausch & Lomb Incorporated Composición de suspensión oftálmica
WO2016195847A1 (en) 2015-06-01 2016-12-08 Duo Security, Inc. Method for enforcing endpoint health standards
CN107024550A (zh) * 2016-12-21 2017-08-08 广州仁恒医药科技股份有限公司 奈帕芬胺眼用药物组合物的质控方法
CN106963730A (zh) * 2016-12-22 2017-07-21 广州仁恒医药科技股份有限公司 高度稳定的奈帕芬胺眼用药物组合物
US10412113B2 (en) 2017-12-08 2019-09-10 Duo Security, Inc. Systems and methods for intelligently configuring computer security
US11658962B2 (en) 2018-12-07 2023-05-23 Cisco Technology, Inc. Systems and methods of push-based verification of a transaction
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
CN114272207B (zh) * 2022-01-21 2023-04-11 山东诺明康药物研究院有限公司 一种纳米晶混悬滴眼液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (de) 1967-07-31 1971-03-24
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
US4503073A (en) 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en) 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
DE3668450D1 (de) 1985-03-14 1990-03-01 Smithkline Dauelsberg 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren.
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
CA1325382C (en) 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
KR20040101499A (ko) * 2002-05-03 2004-12-02 알콘, 인코퍼레이티드 암페낙 또는 네파페낙을 이용한 혈관 내피 성장 인자 매개혈관 장애 치료 방법
CN100341498C (zh) 2003-01-21 2007-10-10 千寿制药株式会社 含有2-氨基-3-(4-溴苯甲酰基)苯乙酸的水成液制剂
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations

Also Published As

Publication number Publication date
JP2012041368A (ja) 2012-03-01
WO2006060618A2 (en) 2006-06-08
US20110015271A1 (en) 2011-01-20
RU2007124638A (ru) 2009-01-10
BRPI0518904B1 (pt) 2023-01-24
DK1819362T3 (da) 2010-10-18
AU2005311738A1 (en) 2006-06-08
ATE476200T1 (de) 2010-08-15
US7834059B2 (en) 2010-11-16
EP1819362A2 (de) 2007-08-22
SI1819362T1 (sl) 2010-10-29
TWI358290B (en) 2012-02-21
WO2006060618A3 (en) 2006-10-19
ES2348249T3 (es) 2010-12-02
ZA200704763B (en) 2008-09-25
US20060122277A1 (en) 2006-06-08
JP2008521926A (ja) 2008-06-26
CA2586807C (en) 2013-01-29
AU2005311738B2 (en) 2011-02-03
PT1819362E (pt) 2010-10-11
MX2007006558A (es) 2007-06-15
AR052252A1 (es) 2007-03-07
US8324281B2 (en) 2012-12-04
US8071648B2 (en) 2011-12-06
CN101068573A (zh) 2007-11-07
TW200626132A (en) 2006-08-01
HK1104225A1 (en) 2008-01-11
JP4968844B2 (ja) 2012-07-04
UY29238A1 (es) 2006-05-31
BRPI0518904A2 (pt) 2008-12-16
US20120029084A1 (en) 2012-02-02
KR20070089687A (ko) 2007-08-31
CY1110780T1 (el) 2015-06-10
PL1819362T3 (pl) 2010-12-31
CA2586807A1 (en) 2006-06-08
EP1819362B1 (de) 2010-08-04
KR101289661B1 (ko) 2013-07-29

Similar Documents

Publication Publication Date Title
ATE476200T1 (de) Topische nepafenac-formulierungen
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
DK1750683T3 (da) Formuleringer med langvarig frigivelse
DE602005012636D1 (de) Erung
DE602005012620D1 (de) Spektroskop
DE602005026361D1 (de) Make-up Zubereitung
ATE392425T1 (de) Thiazolyl-dihydro-indazole
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE412651T1 (de) Pyrrolopyridinderivate
ATE459633T1 (de) Makrolide
DK1868586T3 (da) Antiinflammatorisk formulering
DK1778723T3 (da) Il-1-antagonistformuleringer
DE112005001940A5 (de) Skate-Schuh
DE502004006772D1 (de) Wirkwerkzeug-Barre
DK2119472T3 (da) Hud-/hårbehandlingssystem
AT500198B8 (de) Ladewagen
DE602005022667D1 (de) Haartrockner
AT500249A3 (de) Scheibenegge
SE0601411L (sv) Förfarande vid beredning
AT7802U3 (de) Parfum-zerstäuber
ATA482004A (de) Tuba-dämpfer
ATA9982004A (de) Tiefbohrbrunnen
SE0402678D0 (sv) Pharmaceutical use
SE0402639D0 (sv) Pharmaceutical use
SE0402638D0 (sv) Pharmaceutical use